Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Braz J Med Biol Res ; 51(7): e7288, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29742267

RESUMEN

Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, some patients remain anemic even after receiving this medication. This study aimed to investigate the factors associated with resistance to recombinant human erythropoietin therapy with epoetin alfa (αEPO). We performed a prospective, longitudinal study of hemodialysis patients receiving treatment with αEPO at our reference hospital from July 2015 to June 2016. Clinical data was collected, and the response to αEPO treatment was evaluated using the erythropoietin resistance index (ERI). The ERI was defined as the weekly weight-adjusted αEPO dose (U/kg per week)/hemoglobin level (g/dL). A longitudinal linear regression model was fitted with random effects to verify the relationships between clinical and laboratory data and ERI. We enrolled 99 patients (average age, 45.7 (±17.6) years; male, 51.5%; 86.8% with hypertension). The ERI showed a significant positive association with serum ferritin and C-reactive protein, percentage interdialytic weight gain, and continuous usage of angiotensin receptor blocker (ARB) hypertension medication. The ERI was negatively associated with serum iron and albumin, age, urea reduction ratio, and body mass index. Our findings indicate that resistance to αEPO was related to a low serum iron reserve, an inflammatory state, poor nutritional status, and continuous usage of ARBs.


Asunto(s)
Anemia/tratamiento farmacológico , Anemia/etiología , Resistencia a Medicamentos/efectos de los fármacos , Epoetina alfa/uso terapéutico , Hematínicos/uso terapéutico , Diálisis Renal/efectos adversos , Insuficiencia Renal Crónica/terapia , Adulto , Índice de Masa Corporal , Eritropoyesis/efectos de los fármacos , Eritropoyetina/deficiencia , Femenino , Hemoglobinas/análisis , Humanos , Hierro/sangre , Modelos Lineales , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Valores de Referencia , Insuficiencia Renal Crónica/complicaciones , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA